Twitter | Search | |
Search Refresh
Yale Urology May 10
"So we concluded that this is a viable treatment option for those patients with previous chemotherapy for urothelial carcinoma." Watch Dr. Dan Petrylak talk about the exciting results of the RANGE Trial at in Madrid.
Reply Retweet Like
Elizabeth Plimack MD 4 Nov 17
Axel Bex: challanges/lessons from cytoreductive nephrectomy RCTs . ICYMI : deferred ?better than upfront CN 4 met
Reply Retweet Like
Bishal Gyawali 10 Oct 17
I know that feeling. At poster I was asked "but you can't ignore the PFS benefit these drugs are providing".
Reply Retweet Like
ESMO - Eur. Oncology Apr 11
What happens when meets !
Reply Retweet Like
ESMO - Eur. Oncology 3 Oct 17
Wishing Women for Oncology Italy all the best for their post- focus meeting taking place today in Milan!
Reply Retweet Like
Jay 21 Sep 17
& the folk at are on top of the misleading data story. ... The little guy data better
Reply Retweet Like
Ricardo Carvalho 29 Sep 17
Replying to @myESMO @mesmo
The presentations of "poster discussion" are NOT available too... ? Only abstracts of these sessions . Do you know when they will be available?
Reply Retweet Like
Jacob Plieth May 18
Replying to @JacobPlieth
confirmed that the $62m Imfinzi number is almost entirely NSCLC, after NCCN guidelines inclusion post
Reply Retweet Like
BLCAC 7 Oct 17
The latest The Bettye Harris Herald! Thanks to
Reply Retweet Like
Dr. Paul DeSantis 12 Dec 17
Replying to @BldCancerDoc
super early sessions can be tough jet lag etc like at
Reply Retweet Like
ZIA 26 Sep 17
ROUNDUP: Merck's data on Keytruda/chemo combo for lung cancer takes early spotlight at ESMO
Reply Retweet Like
Novartis Cancer 21 Sep 17
US Only: Attention US health care providers! If you missed , you can register to view virtual sessions here:
Reply Retweet Like
Ricardo Carvalho 24 Sep 17
Will you make it available on Webcast the "proffered paper sessions" of ? Only abstracts of these session R available so far
Reply Retweet Like
Jacob Plieth Mar 22
Replying to @BrianSkorney
"Immunotherapy that in some clinical settings is superior to TKIs" is far more guarded than B Escudier's "practice-changing, new SOC" claim at
Reply Retweet Like
Veristat, LLC 21 Sep 17
Theresa Bruce highlights the latest discussed at .
Reply Retweet Like
Novartis Cancer 5 Oct 17
US Only: Novartis is providing virtual access to sessions you might have missed. US HCPs, register here: .
Reply Retweet Like
medwireNews 23 Nov 17
We spoke to study author Suresh Ramalingam at - check out our video interview with him
Reply Retweet Like
Novartis Cancer 30 Sep 17
US Only: Virtual access is still available for US HCPs who missed out on sessions from . To register, visit .
Reply Retweet Like
ESMO - Eur. Oncology Oct 17
Getting excited about ? Take a look back at key moments from in Madrid - guaranteed to heighten expectations here in Munich!
Reply Retweet Like
Jacob Plieth Aug 23
Replying to @JacobPlieth
My take on PI3k inhibition in breast cancer, from
Reply Retweet Like